Access to generic lenalidomide (e.g. Revlimid) in Europe

Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here.    Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings.   Lenalidomide was first approved by the European Medicines Agency (EMA) in 2008 and has been solely marketed in Europe by Celgene…

Myeloma Patients Europe appoints Interim CEO

Myeloma Patients Europe (MPE) is pleased to share that Hans Scheurer, President of MPE, will be acting as Interim Chief Executive Officer (CEO) until a permanent CEO is appointed in the coming months.   This follows last year’s news that the founding CEO of MPE, Ananda Plate, has stood down from the role after ten very successful years.   Hans will be supported in his role as Interim CEO by a formal management committee, who…